Guidepoint Qsight’s proprietary Aesthetics data examines patient spending in the United States, providing insight into brand retention in the Neurotoxin…
Point-of-Sale
Guidepoint Qsight’s data captured a surge in spending on non-surgical medical aesthetics treatments in March and April 2021. Neurotoxins, dermal…
Guidepoint Qsight is excited to announce the launch of a new Medical Aesthetics market intelligence offering where you can track…
![shutterstock_1192579135-[Converted]](https://qsight.guidepoint.com/wp-content/uploads/2021/07/shutterstock_1192579135-Converted.jpg)
With COVID-19 continuing to create uncertainty, Guidepoint Qsight has gathered insights from U.S. physicians across healthcare markets on their expected…
Following temporary bans on elective procedures earlier this year due to the COVID-19 pandemic, Guidepoint Qsight was able to capture…